The Obstacles to Real Health Care Reform: Private Insurers and Big PhRMA - by Stephen Lendman
In almost the same breath on August 17, the White House effectively dropped a real public option (that likely never existed) while Obama was telling the Veterans of Foreign Wars (VFW) that the Pentagon will escalate the Afghanistan/Pakistan war into a long-term conflict that will assure "more difficult days ahead." He did so in defiance of international and Constitutional law, the lives and welfare of American forces, millions in both target countries, and lied at the same time saying: "This is not a war of choice. This is a war of necessity" in plain contradiction of the fact that in October 2001, US forces launched a long-planned premeditated attack against a non-belligerent country posing no threat to America.
Obama's Central Asia agenda matches his domestic arrogance against the rights and welfare of millions of Americans. Denying them real health care reform is one of many ways he defiles the public interest in deference to the corporate ones he serves.
On financial matters, it's trillions for Wall Street. On "defense," it's imperial wars and handouts to weapons and munitions makers, and on public health it's promoting mass-innoculations of experimental, toxic vaccines and rejecting real health care reform - universal single-payer, the only real kind that all other Western nations provide. But not the richest country in the world more focused on corporate than public welfare.
Simply put, the obstacle to real health reform is the insurance and drug lobby's stranglehold on Democrat and Republican administrations and Congress. Corporate lawyers draft new laws, sign-off on changes, and industry officials staff the FDA, CDC, and other related agencies, then return to high-paying jobs in the sectors they represent. Public welfare is unconsidered under a system favoring profits, so achieving real reform is near-nil. Whatever, if any legislation, passes, will make a dysfunctional system worse by rationing care, leaving growing millions uninsured, many others underinsured, while enriching insurers, drug companies, and large hospital chains.
Predatory Drug Giants
Called Big PhRMA with good reason, they wield inordinate power over policies affecting their industry. Poorly tested new drugs are fast-tracked and only withdrawn after hundreds, often thousands, are harmed. Yet no congressional committee ever investigated a process endangering millions of lives because lawmakers reap huge campaign contributions regularly in return for industry-friendly legislation and regulations.
In January 1997, Rezulin got swift FDA approval to control blood sugar for patients with Type 2 (non-insulin-dependent) diabetes. It was only withdrawn in March 2000 after dozens of liver failure deaths were reported and many others found to be afflicted with serious, potentially life threatening damage.